{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:12:11Z","timestamp":1787731931861,"version":"build-2784847793"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ind Psychiatry J"],"published-print":{"date-parts":[[2014]]},"DOI":"10.4103\/0972-6748.151703","type":"journal-article","created":{"date-parts":[[2015,2,18]],"date-time":"2015-02-18T04:40:37Z","timestamp":1424234437000},"page":"163","source":"Crossref","is-referenced-by-count":8,"title":["Catatonia versus neuroleptic malignant syndrome: the diagnostic dilemma and treatment"],"prefix":"10.4103","volume":"23","author":[{"given":"ManojKumar","family":"Sahoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshita","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0972-6748.151703-1","first-page":"121","volume-title":"Treating neuroleptic malignant syndrome as catatonia","author":"Fink","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"key-10.4103\/0972-6748.151703-2","first-page":"404","volume-title":"Glutamatergic dysfunction in catatonia.Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine?","author":"Northoff","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.4103\/0972-6748.151703-3","first-page":"1","volume-title":"Neuroleptic malignant syndrome and catatonia: One entity or two?","author":"Fink","year":"1996","journal-title":"Biol Psychiatry"},{"key":"key-10.4103\/0972-6748.151703-4","first-page":"347","volume-title":"Catatonia, lethal catatonia and neuroleptic malignant syndrome","author":"Fricchione","year":"2000","journal-title":"Psychiatry Ann"},{"key":"key-10.4103\/0972-6748.151703-5","first-page":"1113","volume-title":"Novel antipsychotics and the neuroleptic malignant syndrome: A review and critique","author":"Hasan","year":"1998","journal-title":"Am J Psychiatry"},{"key":"key-10.4103\/0972-6748.151703-6","first-page":"79","volume-title":"The neuroleptic malignant syndrome","author":"Caroff","year":"1980","journal-title":"J Clin Psychiatry"},{"key":"key-10.4103\/0972-6748.151703-7","first-page":"499","volume-title":"Neuroleptic toxicity syndromes: A clinical spectrum","author":"Reilly","year":"1991","journal-title":"Aust N Z J Psychiatry"},{"key":"key-10.4103\/0972-6748.151703-8","first-page":"1006","volume-title":"Neuroleptic malignant syndrome: A case report with post-mortem brain and muscle pathology","author":"Jones","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.4103\/0972-6748.151703-9","first-page":"129","volume-title":"Neuroleptic malignant syndrome","author":"Adnet","year":"2000","journal-title":"Br J Anaesth"},{"key":"key-10.4103\/0972-6748.151703-10","first-page":"323","volume-title":"The role of creatine kinase in the diagnosis of neuroleptic malignant syndrome","author":"O\u2032Dwyer","year":"1993","journal-title":"Psychol Med"},{"key":"key-10.4103\/0972-6748.151703-11","first-page":"89","volume-title":"Neuroleptic malignant syndrome: Don\u2032t let your guard down yet","author":"Zarrouf","year":"2007","journal-title":"Curr Psychiatry"},{"key":"key-10.4103\/0972-6748.151703-12","doi-asserted-by":"crossref","unstructured":"Dhossche DM, Carroll BT, Carroll TD, In: Dhossche D, Wing ML, Ohta M, Neumarker K, editors. Is there a Common Neuronal Basis for Autism and Catatonia? Catatonia in Autism Spectrum Disorders. St. Louis, MO: Elsevier\/Academic Press, Inc.; 2006.","DOI":"10.1016\/S0074-7742(05)72009-2"},{"key":"key-10.4103\/0972-6748.151703-13","first-page":"1161","volume-title":"Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome","author":"Woodbury","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"key-10.4103\/0972-6748.151703-14","first-page":"98","volume-title":"Olanzapine induced neuroleptic malignant syndrome","author":"Patra","year":"2013","journal-title":"Indian J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0253-7613","issn-type":"print"},{"key":"key-10.4103\/0972-6748.151703-15","first-page":"161","volume-title":"Subjective experience of akinesia in catatonia and Parkinson\u2032s disease","author":"Northoff","year":"1988","journal-title":"Cogn Neuropsychiatry"},{"key":"key-10.4103\/0972-6748.151703-16","first-page":"1156","volume-title":"Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome","author":"Tsai","year":"2005","journal-title":"Pharmacotherapy"},{"key":"key-10.4103\/0972-6748.151703-17","first-page":"129","volume-title":"Proposed research diagnostic criteria for neuroleptic malignant syndrome","author":"Mathews","year":"1999","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Industrial Psychiatry Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:33:26Z","timestamp":1786649606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0972-6748.151703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"alternative-id":["151703"],"URL":"https:\/\/doi.org\/10.4103\/0972-6748.151703","relation":{},"ISSN":["0972-6748"],"issn-type":[{"value":"0972-6748","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}